Centogene N.V. Races Against Nasdaq Delisting
Centogene NV (CNTG) has released an update.
Centogene N.V., a biotech company, has been granted an extension until August 26, 2024, to meet Nasdaq’s minimum Market Value of Publicly Held Shares requirement and avoid delisting. The company is actively working on a strategic review process, which includes a potential sale, to comply with the listing standards. However, the possibility of achieving these milestones and maintaining its Nasdaq listing remains uncertain.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.